Skip to main content
Clinical Trials/ACTRN12609000108213
ACTRN12609000108213
Not yet recruiting
Phase 2

The utility of 18F-fluro-deoxy-glucose (FDG) and 11C-choline (C) positron emission tomography (PET) scan in men with localised prostate cancer planned for radiotheraupetic management

Austin Health0 sites30 target enrollmentFebruary 16, 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Austin Health
Enrollment
30
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • PSA \> 20 or Gleason score 8\-10 or T stage T3a,T3b or T4
  • Age \> 18 years
  • Eastern Cooperative Oncology Group Performance Status (ECOG) 0 or 1
  • No significant medical or psychiatric illness
  • Written informed consent
  • Be prepared to undergo PET scanning

Exclusion Criteria

  • Any form of prostate malignancy
  • T1\-2c prostate cancer and PSA , 10 and Gleason score \< 7
  • Previous radical prostatectomy
  • Known metastatic prostate cancer
  • Contraindication to MRI
  • Contraindication to androgen ablation
  • Contraindication to PET
  • Commencement of androgen depriavation therapy prior to study entry
  • Previous pelvic radiotherapy
  • Contraindication to radiotherapy

Outcomes

Primary Outcomes

Not specified

Similar Trials